6,201 results match your criteria Lymphoma Mantle Cell

Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells.

Prostaglandins Other Lipid Mediat 2021 Jun 8:106575. Epub 2021 Jun 8.

Department of Medicine Solna, Division of Hematology, Karolinska University Hospital and Institutet, Stockholm, Sweden. Electronic address:

Human B-lymphocytes express 5-lipoxygenase (5-LOX) and 5-LOX activating protein (FLAP) and can convert arachidonic acid to leukotriene B. Mantle cell lymphoma (MCL) cells contain similar amounts of 5-LOX as human neutrophils but the function and mechanism of activation of 5-LOX in MCL cells, and in normal B-lymphocytes, are unclear. Here we show that the intrinsic 5-LOX pathway in the MCL cell line JeKo-1 has an essential role in migration and adherence of the cells, which are important pathophysiological characteristics of B-cell lymphoma. Read More

View Article and Full-Text PDF

The pathologic diagnosis of mantle cell lymphoma.

Histol Histopathol 2021 Jun 11:18351. Epub 2021 Jun 11.

Department of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma usually characterized by t(11;14) (q13;q32), or CCND1 translocation and Cyclin D1 over expression. A very small subset of MCL may lack the t(11;14) (q13;q32) translocation and Cyclin D1 over expression, but show alternative translocations involving CCND2 and CCND3, and over expression of SOX11. In general, MCL has been considered a very aggressive and incurable lymphoma and patients with MCL usually have a poor prognosis. Read More

View Article and Full-Text PDF

Mantle cell lymphoma continues to surprise, and inform!

Blood 2021 Jun;137(23):3158-3160

University of Virginia Cancer Center.

View Article and Full-Text PDF

Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?

Clin Adv Hematol Oncol 2021 Jun;19(6):376-382

Weill Cornell Medicine, New York, New York.

Although chemotherapy has been a mainstay of the frontline treatment of mantle cell lymphoma (MCL) for many years, novel agents-including Bruton kinase inhibitors, immunomodulatory agents, and BCL2 inhibitors-have shown promise in patients with relapsed and refractory disease, and they are also being studied in the frontline setting. This review summarizes the current clinical data for using these novel agents in untreated MCL, both in combination with chemotherapy and singly, and discusses some of the trials currently under way to assess their future potential. Read More

View Article and Full-Text PDF

Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.

Hematol Oncol 2021 Jun;39 Suppl 1:31-38

Department of Medicine III, LMU Hospital, Munich, Germany.

Mantle cell lymphoma (MCL) is clinically characterized by its heterogenous behavior with courses ranging from indolent cases that do not require therapy for years to highly aggressive MCL with very limited prognosis. A better understanding of the complex biology of MCL has already led to the approval of several innovative agents, expanding the landscape of MCL therapies and improving therapeutic options especially for refractory or relapsed disease. Nevertheless, to further optimize MCL treatment, early identification of individual risk profile and risk-adapted, patient-tailored choice of therapeutic strategy needs to be prospectively incorporated in clinical patient management. Read More

View Article and Full-Text PDF

Mantle cell lymphoma, malt lymphoma, small lymphocytic lymphoma and follicular lymphoma of the oral cavity: an update.

J Oral Pathol Med 2021 Jun 8. Epub 2021 Jun 8.

Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil.

Although uncommon, mature small B-cell lymphomas may arise in the oral/maxillofacial area and oral pathologists must be aware of the key characteristics of these neoplasms to perform an accurate diagnosis. In this manuscript we attempted to integrate the currently available data on the clinicopathological features of Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT-L), and Chronic Lymphocytic Leukaemia/ Small Lymphocytic Lymphoma (CLL/SLL) affecting these anatomical regions. An updated descriptive literature review was carried out and a detailed electronic search was done in multiple databases to gather all cases affecting the oral/maxillofacial region and palatine tonsils. Read More

View Article and Full-Text PDF

Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.

Sci Rep 2021 Jun 7;11(1):11896. Epub 2021 Jun 7.

Department of Hematology/Hematology Research Laboratory, West China Hospital, Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, China.

Mantle cell lymphoma (MCL) is a relatively rare subtype of non-Hodgkin's lymphoma. To identify molecular biomarkers in MCL, we performed immunohistochemistry tissue arrays using biopsies from 64 MCL patients diagnosed in West China Hospital from 2012 to 2016. TP53 mutation status in those patients was also examined by sequencing. Read More

View Article and Full-Text PDF

Extremely Rare Primary Spinal Epidural Indolent Mantle Cell Lymphoma: A Case Report With Literature Review.

Cureus 2021 Apr 29;13(4):e14762. Epub 2021 Apr 29.

Orthopaedics, Tribhuvan University Institute of Medicine, Kathmandu, NPL.

Lymphomas are malignant tumors arising from lymphoid tissues and can spread to other organs. Primary extra-nodal locations such as the spinal epidural space are less common. Primary spinal epidural lymphoma (PSEL), which can be either Hodgkin's or non-Hodgkin's type, is rare. Read More

View Article and Full-Text PDF

Involved in Innate Immunity by Activating Tyrosinase-Mediated Melanin Synthesis in .

Front Immunol 2021 20;12:626493. Epub 2021 May 20.

Fishery College, Guangdong Ocean University, Zhanjiang, China.

The microphthalmia-associated transcription factor (MITF) is an important transcription factor that plays a key role in melanogenesis, cell proliferation, survival and immune defense in vertebrate. However, its function and function mechanism in bivalve are still rarely known. In this research, first, a gene was characterized from (). Read More

View Article and Full-Text PDF

Real World Treatment Practices for Mantle Cell Lymphoma in Japan: An Observational Database Research Study (CLIMBER-DBR).

J Clin Exp Hematop 2021 Jun 5. Epub 2021 Jun 5.

Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Mantle cell lymphoma (MCL) accounts for approximately 3% of all cases of malignant lymphoma in Japan. The CLIMBER-DBR (Treatment practices and patient burden in chronic lymphocytic leukemia and mantle cell lymphoma patients in the real world: An observational database research in Japan) study examined the clinical characteristics, treatment patterns, and healthcare resource utilization of MCL in a real-world clinical setting in Japan. Using the Japanese Medical Data Vision database, we extracted data for 1130 patients with MCL (ICD-10 code C83. Read More

View Article and Full-Text PDF

Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis.

Leuk Res 2021 May 3;108:106605. Epub 2021 May 3.

Department of Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu, 610072, Sichuan, China. Electronic address:

Some studies have elucidated that Minimal residual disease (MRD) in patient with Mantle Cell Lymphoma (MCL) was a significant prognostic factor, with potential value in assessing overall survival (OS) and progression-free survival (PFS). However, most studies were widely varied in included population, sample sources and MRD detection time points. Some studies even have conflicting results. Read More

View Article and Full-Text PDF

Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase 1, First-in-Human Study.

Clin Cancer Res 2021 Jun 3. Epub 2021 Jun 3.

Haematology, Peter MacCallum Centre, Melbourne.

Purpose: We previously reported a 44% overall response rate (ORR) with venetoclax in a phase 1 study of relapsed/refractory NHL. Complete remission (CR) was observed in patients with mantle cell lymphoma ([MCL], 21%, n=6/28) and follicular lymphoma ([FL], 17%, n=5/29), and partial response (PR) noted in several patients with Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL). Here, we report the long-term outcomes of these four cohorts. Read More

View Article and Full-Text PDF

LYNX (LYmphoid NeXt-generation sequencing) panel: a comprehensive capture-based sequencing tool for the analysis of prognostic and predictive markers in lymphoid malignancies.

J Mol Diagn 2021 May 31. Epub 2021 May 31.

Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital Brno, Czech Republic; Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Czech Republic. Electronic address:

B-cell neoplasms represent a clinically heterogeneous group of hematological malignancies with considerably diverse genomic architecture recently endorsed by next-generation sequencing (NGS) studies. Since multiple genetic defects have potential or confirmed clinical impact, a tendency toward more comprehensive testing of diagnostic, prognostic, and predictive markers is desired. In this study, we introduce the design, validation, and implementation of an integrative custom-designed capture-based NGS panel titled LYNX (LYmphoid NeXt-generation sequencing) for the analysis of standard and novel molecular markers in the most common lymphoid malignancies (chronic lymphocytic leukemia, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma). Read More

View Article and Full-Text PDF

Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.

Leuk Lymphoma 2021 Jun 3:1-11. Epub 2021 Jun 3.

Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Mantle cell lymphoma (MCL) is an aggressive B-cell neoplasm that follows a heterogeneous clinical course. Recurrent mutations have been described, but their applicability in the clinical setting is currently limited. The main reasons are challenges in the sequencing of DNA retrieved from formalin-fixed tissue commonly used for tissue collection in clinical biobanks. Read More

View Article and Full-Text PDF

Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.

Infect Agent Cancer 2021 Jun 2;16(1):38. Epub 2021 Jun 2.

Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Naples, Italy.

Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which may generate unusual COVID-19 dynamics and pose unique management challenges. We report the unusual clinical course of COVID-19 in a patient with mantle cell lymphoma (MCL) exposed to nine doses of Rituximab shortly before infection with severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). Read More

View Article and Full-Text PDF

Twists and Turns from 'Tumor in Tumor' Profiling: Surveillance of CLL leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis.

Cold Spring Harb Mol Case Stud 2021 Jun 1. Epub 2021 Jun 1.

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, 02115, United States;

Comprehensive characterization of somatic genomic alterations has led to fundamental shifts in our understanding of tumor biology. In clinical practice, these studies can lead to modifications of diagnosis and/or specific treatment implications, fulfilling the promise of personalized medicine. Herein, we describe a 78-year old woman under surveillance for long-standing untreated chronic lymphocytic leukemia (CLL). Read More

View Article and Full-Text PDF

Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome after High-Dose Chemotherapy.

Cancers (Basel) 2021 May 23;13(11). Epub 2021 May 23.

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, 72076 Tübingen, Germany.

Novel predictive factors are needed to identify mantle cell lymphoma (MCL) patients at increased risk for relapse after high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HDCT/Auto-HSCT). Although bone marrow and peripheral blood involvement is commonly observed in MCL and lymphoma cell contamination of autologous stem cell grafts might facilitate relapse after Auto-HSCT, prevalence and prognostic significance of residual MCL cells in autologous grafts are unknown. We therefore performed a multiparameter flow cytometry (MFC)-based measurable residual disease (MRD) assessment in autologous stem cell grafts and analyzed its association with clinical outcome in an unselected retrospective cohort of 36 MCL patients. Read More

View Article and Full-Text PDF

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?

Cancers (Basel) 2021 May 20;13(10). Epub 2021 May 20.

Department of Neurosurgery, Division of Neuro-Oncology, Ludwig Maximilians University School of Medicine, Marchioninistrasse, 1581377 Munich, Germany.

Primary CNS lymphomas (PCNSL) represent a group of extranodal non-Hodgkin lymphomas and secondary CNS lymphomas refer to secondary involvement of the neuroaxis by systemic disease. CNS lymphomas are associated with limited prognosis even after aggressive multimodal therapy. Chimeric antigen receptor (CAR) T-cells have proven as a promising therapeutic avenue in hematological B-cell malignancies including diffuse large B-cell lymphoma, B-cell acute lymphoblastic leukemia, and mantle-cell lymphoma. Read More

View Article and Full-Text PDF

Flow cytometric expression of CD71, CD81, CD44 and CD39 in B cell lymphoma.

Scand J Clin Lab Invest 2021 May 31:1-5. Epub 2021 May 31.

Hematology Laboratory,ICO-Hospital Germans Trias i Pujol, LUMN, IJC-Functional Cytomics unit, UAB, Badalona, Spain.

Flow cytometry is a useful ancillary tool for the diagnosis of nodal B cell lymphomas. Well-established antigens have diagnostic limitations. This study aimed to assess the expression of CD71, CD81, CD44 and CD39 by flow cytometry in B cell lymphomas. Read More

View Article and Full-Text PDF

Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.

Front Oncol 2021 14;11:668162. Epub 2021 May 14.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Bruton tyrosine kinase (BTK) is a validated target for treatment of B-cell malignancies, and oral inhibitors of BTK have emerged as a standard of care for these diseases. Acalabrutinib is a second generation, highly selective, potent, covalent BTK inhibitor that exhibits minimal off-target activity in assays, providing the potential to improve tolerability over the first-in-class BTK inhibitor, ibrutinib. Acalabrutinib was approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) in the US in 2017 and 2019, respectively. Read More

View Article and Full-Text PDF

Zanubrutinib-induced liver injury: a case report and literature review.

BMC Gastroenterol 2021 May 29;21(1):244. Epub 2021 May 29.

Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK.

Background: Zanubrutinib is a Bruton's tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no reported cases of hepatotoxicity secondary to zanubrutinib. We report the first case of severe liver injury due to zanubrutinib. Read More

View Article and Full-Text PDF

M3258 is a selective inhibitor of the immunoproteasome subunit LMP7 (β5i) delivering efficacy in multiple myeloma models.

Mol Cancer Ther 2021 May 27. Epub 2021 May 27.

Merck KGaA, Biopharma Research & Development, Frankfurter Str. 250, 64293 Darmstadt, Germany.

Large multifunctional peptidase 7 (LMP7/β5i/PSMB8) is a proteolytic subunit of the immunoproteasome, which is predominantly expressed in normal and malignant hematolymphoid cells, including multiple myeloma (MM), and contributes to the degradation of ubiquitinated proteins. Described herein for the first time is the preclinical profile of M3258; an orally-bioavailable, potent, reversible and highly-selective LMP7 inhibitor. M3258 demonstrated strong antitumor efficacy in MM xenograft models, including a novel model of the human bone niche of MM. Read More

View Article and Full-Text PDF

3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.

Cancer Cell Int 2021 May 26;21(1):279. Epub 2021 May 26.

Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 935 Jiaoling Road, Kunming, 650118, Yunnan, China.

Background: Bortezomib (BTZ) is an inhibitor of the proteasome that has been used to treat patients with mantle cell lymphoma (MCL), but the resistance to BTZ in clinical cases remains a major drawback. BACH2 is a lymphoid-specific transcription repressor recognized as a tumor suppressor in MCL. Reduced BACH2 levels contribute to BTZ resistance; however, the molecular events underlying BACH2-mediated BTZ resistance are largely unclear. Read More

View Article and Full-Text PDF

Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.

Sci Rep 2021 May 25;11(1):10883. Epub 2021 May 25.

Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, PRB, 720 S. Donahue Dr., Auburn, AL, 36849, USA.

Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the treatment of acute lymphoblastic leukemia (ALL). The t(4;11)(q21;q23) chromosomal translocation that leads to the expression of MLL-AF4 fusion protein and confers a poor prognosis, is the major cause of infant ALL. This translocation sensitizes tumor cells to proteasome inhibitors, but toxicities of bortezomib and carfilzomib may limit their use in pediatric patients. Read More

View Article and Full-Text PDF

Identification of miRNA-34a and miRNA-155 as prognostic markers for mantle cell lymphoma.

J Int Med Res 2021 May;49(5):3000605211016390

Department of Hematology, Shanxi Provincial People's Hospital Affiliated with Shanxi Medical University, Taiyuan 030012, China.

Objective: MicroRNAs (miRNAs) with functional relevance have not been previously identified in mantle cell lymphoma (MCL). Here, we aimed to evaluate the relationships between miR-34a and miR-155-5p and MCL clinicopathology and prognosis.

Methods: Seventy-five paraffin-embedded tissue samples from patients with MCL who completed at least four cycles of chemotherapy from January 2006 to October 2016, and 27 samples from control patients with reactive lymphoid hyperplasia (RLH), were collected. Read More

View Article and Full-Text PDF

Blastoid mantle cell lymphoma: cutaneous infiltration.

An Bras Dermatol 2021 May 18. Epub 2021 May 18.

Department of Dermatology, Faculty of Medicine, Universidade Estadual Paulista, São Paulo, SP, Brazil. Electronic address:

Mantle cell lymphoma is an aggressive B-cell, non-Hodgkin's lymphoma, with lymph node or extranodal origin, and a mean survival of three to five years. Skin involvement is rare, secondary and indicates neoplasia dissemination. The authors report a case of a female patient, 69 years old, diagnosed previously, after lymph node and bone marrow biopsy. Read More

View Article and Full-Text PDF

Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.

Br J Haematol 2021 May 18. Epub 2021 May 18.

Department of Computer Sciences, University of Torino, Torino, Italy.

Minimal residual disease (MRD) determined by classic polymerase chain reaction (PCR) methods is a powerful outcome predictor in mantle cell lymphoma (MCL). Nevertheless, some technical pitfalls can reduce the rate of of molecular markers. Therefore, we applied the EuroClonality-NGS IGH (next-generation sequencing immunoglobulin heavy chain) method (previously published in acute lymphoblastic leukaemia) to 20 MCL patients enrolled in an Italian phase III trial sponsored by Fondazione Italiana Linfomi. Read More

View Article and Full-Text PDF

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.

Nat Commun 2021 05 17;12(1):2877. Epub 2021 May 17.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

The mechanisms driving therapeutic resistance and poor outcomes of mantle cell lymphoma (MCL) are incompletely understood. We characterize the cellular and molecular heterogeneity within and across patients and delineate the dynamic evolution of tumor and immune cell compartments at single cell resolution in longitudinal specimens from ibrutinib-sensitive patients and non-responders. Temporal activation of multiple cancer hallmark pathways and acquisition of 17q are observed in a refractory MCL. Read More

View Article and Full-Text PDF

Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population.

BMC Cancer 2021 May 17;21(1):566. Epub 2021 May 17.

Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore City, 169610, Singapore.

Background: Significant progress has been made in the treatment outcomes of mantle cell lymphoma (MCL) since the introduction of cytarabine and rituximab in modern regimens. However, older patients may not readily tolerate these agents nor derive benefit. We investigated the impact of age on treatment patterns and clinical outcomes of MCL patients in an Asian population. Read More

View Article and Full-Text PDF

Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.

Bioorg Chem 2021 Jul 7;112:104968. Epub 2021 May 7.

Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, PR China. Electronic address:

Ibrutinib, a potent irreversible Bruton's tyrosine kinase (BTK) inhibitor, was approved by the FDA for treating mantle cell lymphoma (MCL). Although ibrutinib exhibited excellent antitumor activity, it was associated with certain adverse reactions, with off-target effects against EGFR, Itk and Src family kinases. Our studies yielded a novel series of substituted benzyl pyrrolopyrimidine derivatives capable of potent inhibition of BTK. Read More

View Article and Full-Text PDF